FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4385727311> ?p ?o ?g. }

• W4385727311 endingPage "e1883658" @default.
• W4385727311 startingPage "e1883658" @default.
• W4385727311 abstract "Topic: 22. Stem cell transplantation - Clinical Background: Approximately, 40% patients receiving high dose melphalan (HDM) develop grade III or IV diarrhea (CTCAE 5.0) that promptly improves upon neutrophilic engraftment. Persistence of grade III diarrhea beyond 24 hours post engraftment, though uncommon results in significant morbidity and prolongs hospitalization. Aims: To Explore role of oral Budesonide for patients with persistent diarrhea following high dose melphalan based chemotherapy conditioning Methods: Histopathologic finding of colonic crypt inflammation in a patient (first on table 1) led to utilization of short course of oral budesonide (BUD) resulting in rapid and sustained resolution of diarrhea. We herein document 5 such cases and discuss its role in reducing morbidity and duration of hospitalization. Persistent grade III diarrhea 24 hours after neutrophil engraftment defined protracted diarrhea from melphalan. Infectious workup including stool examination for salmonella, shigella, rotavirus, cryptosporidium, clostridium difficile were performed. Results: The median age of 5 patients was 64 (range, 44-73) years (Females=3, Males=2). A total of 3 patients with multiple myeloma received melphalan 200 mg/m2 while 1 with associated renal failure received Melphalan 140 mg/m2. One patient with Hodgkin’s lymphoma also received melphalan 140 mg/m2 (table 1). Median time to neutrophilic engraftment following autologous stem cell transplant (ASCT) was day +12 (range, 10-12) days. negative. Colonoscopy in one patient confirmed patchy crypt apoptosis and crypt abscess formation. Standard supportive care including antidiarrheals offered no improvement. Oral budesonide (BUD)was introduced at median of 2 (range, 1-11) days from engraftment. The median cumulative dose of BUD comprised 12 mg (range, 9-72 mg). Four patients had rapid resolution of diarrhea within 24 hours, while 5th patient improved in 7 days. Median duration of BUD was 2 (range, 1-7) days. Median time to discharge from BUD initiation was 2 days (range 1-7). An additional patient was excluded from analysis as his stool tested positive for rotavirus; he too promptly responded to BUD. Summary/Conclusion: In absence of systemic studies, we postulate that reduction in gut inflammation improves diarrhea. We do not think these diarrheas were related to autologous graft versus host disease. We did not observe any untoward effects of such short courses of BUD. Palifermin, a recombinant human keratinocyte growth factor is effective in reducing diarrhea of HDM. However, its cost is prohibitive. Oral BUD results in rapid resolution of lower GI toxicity of HDM and potentially lowers cost of hospitalization.Keywords: Autologous hematopoietic stem cell transplantation" @default.
• W4385727311 created "2023-08-11" @default.
• W4385727311 creator A5014839531 @default.
• W4385727311 creator A5015085953 @default.
• W4385727311 creator A5021778452 @default.
• W4385727311 creator A5062116571 @default.
• W4385727311 creator A5065148715 @default.
• W4385727311 creator A5076444048 @default.
• W4385727311 date "2023-08-01" @default.
• W4385727311 modified "2023-09-27" @default.
• W4385727311 title "PB2463: PROTRACTED DIARRHEA FROM HIGH-DOSE MELPHALAN IN AUTOLOGOUS HEMATOPOIETIC TRANSPLANTATION: RESPONSE TO SHORT COURSE OF ORAL BUDESONIDE" @default.
• W4385727311 doi "https://doi.org/10.1097/01.hs9.0000976556.18836.58" @default.
• W4385727311 hasPublicationYear "2023" @default.
• W4385727311 type Work @default.
• W4385727311 citedByCount "0" @default.
• W4385727311 crossrefType "journal-article" @default.
• W4385727311 hasAuthorship W4385727311A5014839531 @default.
• W4385727311 hasAuthorship W4385727311A5015085953 @default.
• W4385727311 hasAuthorship W4385727311A5021778452 @default.
• W4385727311 hasAuthorship W4385727311A5062116571 @default.
• W4385727311 hasAuthorship W4385727311A5065148715 @default.
• W4385727311 hasAuthorship W4385727311A5076444048 @default.
• W4385727311 hasBestOaLocation W43857273111 @default.
• W4385727311 hasConcept C126322002 @default.
• W4385727311 hasConcept C141071460 @default.
• W4385727311 hasConcept C2777408962 @default.
• W4385727311 hasConcept C2778684742 @default.
• W4385727311 hasConcept C2779802037 @default.
• W4385727311 hasConcept C2911091166 @default.
• W4385727311 hasConcept C71924100 @default.
• W4385727311 hasConcept C90924648 @default.
• W4385727311 hasConceptScore W4385727311C126322002 @default.
• W4385727311 hasConceptScore W4385727311C141071460 @default.
• W4385727311 hasConceptScore W4385727311C2777408962 @default.
• W4385727311 hasConceptScore W4385727311C2778684742 @default.
• W4385727311 hasConceptScore W4385727311C2779802037 @default.
• W4385727311 hasConceptScore W4385727311C2911091166 @default.
• W4385727311 hasConceptScore W4385727311C71924100 @default.
• W4385727311 hasConceptScore W4385727311C90924648 @default.
• W4385727311 hasIssue "S3" @default.
• W4385727311 hasLocation W43857273111 @default.
• W4385727311 hasLocation W43857273112 @default.
• W4385727311 hasOpenAccess W4385727311 @default.
• W4385727311 hasPrimaryLocation W43857273111 @default.
• W4385727311 hasRelatedWork W1586374228 @default.
• W4385727311 hasRelatedWork W2003938723 @default.
• W4385727311 hasRelatedWork W2047967234 @default.
• W4385727311 hasRelatedWork W2118496982 @default.
• W4385727311 hasRelatedWork W2364998975 @default.
• W4385727311 hasRelatedWork W2369162477 @default.
• W4385727311 hasRelatedWork W2413988841 @default.
• W4385727311 hasRelatedWork W2439875401 @default.
• W4385727311 hasRelatedWork W4238867864 @default.
• W4385727311 hasRelatedWork W2525756941 @default.
• W4385727311 hasVolume "7" @default.
• W4385727311 isParatext "false" @default.
• W4385727311 isRetracted "false" @default.
• W4385727311 workType "article" @default.